Global High Potency API /HPAPI Market

1 INTRODUCTION OF GLOBAL HIGH POTENCY API /HPAPI MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HIGH POTENCY API /HPAPIMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL HIGH POTENCY API /HPAPI MARKET, BY THERAPEUTIC APPLICATION:
5.1 Oncology
5.2 Hormonal Imbalance
5.3 Glaucoma
5.4 Other Therapeutic Applications

6 GLOBAL HIGH POTENCY API /HPAPI MARKET, BY TYPE OF MANUFACTURERS:
6.1 Captive Manufacturers
6.2 Merchant Manufacturers
6.3 Merchant HPAPI Manufacturers Market, By Type
6.3.1 Innovative Merchant HPAPI Manufacturers
6.3.2 Generic Merchant HPAPI Manufacturers
6.4 Merchant HPAPI Manufacturers Market, By Type of Synthesis
6.4.1 Synthetic HPAPIs
6.4.2 Biotech HPAPIs

7 GLOBAL HIGH POTENCY API /HPAPI MARKET, BY TYPE OF SYNTHESIS:
7.1 Synthetic High Potency Active Pharmaceutical Ingredients
7.2 Synthetic High Potency Active Pharmaceutical Ingredients Market, By Type
7.2.1 Innovative Synthetic HPAPIs
7.2.2 Generic Synthetic HPAPIs
7.3 Biotech High Potency Active Pharmaceutical Ingredients
7.3.1 Biotech High- potency Active Pharmaceutical Ingredients Market, By Type
7.3.1.1 Innovative Biotech HPAPIs
7.3.1.2 Bio-similars

8 GLOBAL HIGH POTENCY API /HPAPI MARKET, BY TYPE:
8.1 Innovative High Potency Active Pharmaceutical Ingredients
8.2 Generic High Potency Active Pharmaceutical Ingredients

9 GLOBAL HIGH POTENCY API /HPAPIMARKET, BY GEOGRAPHY
9.1 Overview
9.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

10 GLOBAL HIGH POTENCY API /HPAPIMARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES
11.1 Pfizer, Inc.
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments

11.2 Novartis International AG
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments

11.3 Sanofi
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments

11.4 F. Hoffmann-La Roche Ltd.
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments

11.5 Bristol-Myers Squibb
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments

11.6 BoehringerIngelheim
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments

11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments

11.8 ELI Lilly and Company
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments

11.9 Merck & Co., Inc.
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Development

11.10 Abbvie Inc.
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Development

11.11 Mylan N.V.
11.11.1 Overview
11.11.2 Financial Performance
11.11.3 Product Outlook
11.11.4 Key Development

12 Appendix
12.1 Related Reports